Quintiles Sees Shift Towards Specialty Sales; Preps for Cymbalta Launch
Executive Summary
Quintiles is seeing a shift in the contract sales business towards more specialty market products
You may also be interested in...
Lilly Dual-Acting Cymbalta Promoted By Dual Sales Force With Quintiles Deal
Lilly's use of a dual sales force for the antidepressant Cymbalta follows the Evista model
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials